[12] Patent
[11] Patent No.:GC0007648  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126497
Date of the Decision to Grant the Patent:25/Apr/2018

[21] Application No.:GCC/P/2007/8828

[22] Filing Date:1/8/2007

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
4/8/2006
60/835.574

[72] Inventors:1- Syed M. Shah،2- Mahdi B. Fawzi،3- Natalyia Bazhina،4- Christian Ofslager

[73] Owner: Wyeth, Five Giralda Farms, Madison, NJ 07940, USA

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: A61K 31/485, 47/02, 47/18, 9/00 (2006.01)

[56] Cited Documents:

-WO 2004091623 A1 (PROGENICS PHARMACEUTICALS. INC. et al.)28 October 2004
-WO 2004091622 A1 (PROGENICS PHARMACEUTICALS. INC. et al.)28 October. 2004
-WO 03077867 A2 (EUROCELTIQUE,S.A. et al.)25 September. 2003
 
Examiner: PH. Mohammad S. AlMousa

[54] FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF
[57] Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating, delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.
No. of claims: 15     No. of figures: 4


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.